Trial Details

NOT_YET_RECRUITING
Basic Information
Clinical ID c348
Identifier NCT06727422
Trial Title Efficacy of Rifaximin With NAC in IBS-D
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-predominant)
Interventions DRUG: rifaximin 66mg + N-acetylcysteine 560mg three times daily|DRUG: RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily|DRUG: Placebo
Participant Information
Sponsor Mark Pimentel, MD
City -
Country/Region -
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2025-12-15
Primary Completion Date 2026-04-01
Completion Date 2027-01-01